ArticleNeurochemical research2025
Neuroprotective Effects of Formononetin on Traumatic Brain Injury Through miR-155 Modulation of the Nrf2/HO-1 Signalling Pathway.
Article in Neurochemical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring the Neuroprotective Potential ofBiomolecules · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Traumatic brain injury (TBI) is a severe form of cranial trauma that is associated with high disability and mortality rates, imposing substantial physical, psychological, and economic burdens on affected individuals. Formononetin (FN), a well-characterized phytoestrogen, exhibits diverse biological activities, most notably anti-inflammatory and antioxidant effects, and has demonstrated neuroprotective potential in TBI scenarios. Previous studies have shown that FN is capable of upregulating the expression of microRNA-155 (miR-155), nuclear factor erythroid 2-related factor 2 (Nrf2), and heme oxygenase-1 (HO-1) in TBI rat models. However, the precise function of miR-155 and its interaction with the Nrf2/HO-1 pathway remain incompletely elucidated. Herein, we investigated the therapeutic impact of FN on TBI pathophysiology and its underlying neuroprotective mechanisms, with a specific focus on miR-155 inhibition. Our findings showed that FN treatment notably improved neurological function, reduced cerebral edema, attenuated histopathological damage at the site of injury, decreased neuronal apoptosis, enhanced the performance in the Morris water maze, decreased inflammatory cytokine levels, and upregulated the expression of miR-155, Nrf2, and HO-1 in TBI rats. These observations suggest that FN has neuroprotective effects in TBI. Notably, when miR-155 was inhibited, the neuroprotective effects of FN were partially abrogated, accompanied by downregulated Nrf2 and HO-1 expression. This suggests that the protective effects of FN are likely mediated by miR-155-dependent modulation of the Nrf2/HO-1 pathway, providing valuable insights into the potential therapeutic use of FN and its derivatives for TBI management.
Indexed as
Identifiers
41212265What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.